Home Pilots GrayMatters Health receives FDA 510(k) for PTSD neuromodulation therapy Pilots GrayMatters Health receives FDA 510(k) for PTSD neuromodulation therapy By - March 27, 2023 41 0 Facebook Twitter Pinterest WhatsApp The company’s product, Prism, uses neurofeedback to help PTSD patients learn to control their emotional response. RELATED ARTICLESMORE FROM AUTHOR Pilots Medtronic issues voluntary recall of MiniMed insulin pumps Pilots Hybrid primary care company Rezilient Health scores $10M Pilots Empathy Health Technologies raises $2.8M for Sober Sidekick app LEAVE A REPLY Cancel reply Please enter your comment! Please enter your name here You have entered an incorrect email address! Please enter your email address here Save my name, email, and website in this browser for the next time I comment. FOLLOW ME0FansLike0FollowersFollow0SubscribersSubscribe POPULAR ARTICLES NVIDIA, Johnson & Johnson Medtech partner to integrate AI into surgery Pilots - March 22, 2024 0 Mark Cuban Cost Plus Drug Company partners with Latino-focused care startup Pilots - April 4, 2023 0 TytoCare scores exclusive partnership with Idaho healthcare system Pilots - November 29, 2023 0 Employer-focused Progyny acquires Berlin-based fertility benefits platform Apryl Pilots - June 24, 2024 0 Study: VA telehealth expansion lagged in rural areas during COVID-19 Pilots - March 9, 2023 0 POPULAR CATEGORIESPilots2166Applications682Testing237Collaborations15GitHub3